Welcome to our dedicated page for Sintx Technologies news (Ticker: SINT), a resource for investors and traders seeking the latest updates and insights on Sintx Technologies stock.
SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced ceramics and biomaterials company headquartered in Salt Lake City, Utah, with news flow centered on silicon nitride–based medical technologies, implant systems, and infection‑prevention platforms. This news page aggregates company press releases and third‑party coverage so readers can follow developments in its silicon nitride biomaterials, polymer composites, and antipathogenic fabric technologies.
Recent SINTX news highlights regulatory milestones and product launches, including U.S. FDA 510(k) clearance for the SINAPTIC Foot & Ankle Osteotomy Wedge System and the launch of OsseoSculpt, a biologic designed to complement the SINAPTIC wedge portfolio. Updates also cover the company’s focused commercialization plan around infection‑resistant silicon nitride devices and polymer composites, as well as early product revenue from OsseoSculpt.
Investors and industry observers will find coverage of strategic agreements, such as the supply agreement with EVONIK to manufacture SINTX’s proprietary SiN/PEEK compound for AI‑assisted, 3D‑printed, patient‑specific implants. News items also track SINTX’s intellectual‑property progress, including Notices of Allowance from the United States Patent and Trademark Office for composition and method patents covering antipathogenic fibrous materials and fabric technologies.
In addition, SINTX issues releases on capital markets activity and corporate events, including warrant exercises, at‑the‑market offering arrangements, and participation in investor conferences hosted by firms such as H.C. Wainwright and Sidoti & Company. These updates provide context on the company’s financing strategy and investor outreach.
By monitoring this page, readers can review SINTX news related to medical device clearances, biologic product introductions, infection‑prevention patents, financing transactions, and investor presentations, all in one place.
Summary not available.
Summary not available.
Summary not available.
SINTX Technologies has completed renovations and equipment installation at its SINTX Armor facility in Salt Lake City, enhancing its capacity to manufacture high-performance ceramic armor products for personnel, aircraft, and vehicles. This facility spans 10,000 square feet and produces advanced materials like BoroShock and DuraShock, which offer lightweight, high-strength protection against projectiles. Following a strategic acquisition of B4C LLC, SINTX Armor anticipates a strong order book in 2023, aligning with a projected global ceramic armor market growth to USD $3.5 billion by 2027.
Summary not available.
SINTX Technologies, Inc. (NASDAQ: SINT) has announced a public offering of 2,150,000 units, priced at $5.60 each. Each unit consists of one share of common stock or one pre-funded warrant, along with one Class C Warrant and half of one Class D Warrant. The offering is expected to yield approximately $12 million in gross proceeds before expenses and is anticipated to close on February 10, 2023. The securities are offered under SEC regulations, and Maxim Group LLC is serving as the placement agent. SINTX focuses on advanced ceramics, particularly silicon nitride, for medical applications and has a history of product implantation since 2008.
SINTX Technologies reported preliminary unaudited financial results for Q4 2022 and the full year, highlighting a revenue of approximately $770k in Q4 and $1.6 million for the year. This marks a consistent quarter-on-quarter growth, surpassing previous annual revenues since selling its spine business in 2018. Government contracts contributed $521k in Q4 and $962k for the year, while commercial revenue from aerospace, energy, dental, and spine sectors reached $248k in Q4 and $602k annually. The company expects growth in 2023 and anticipates the Armor facility in Salt Lake City to be operational by Q1.
SINTX Technologies (NASDAQ: SINT) has announced it has regained compliance with NASDAQ's minimum bid price requirements. The company confirmed that its common stock closed at $1.00 or more per share for ten consecutive business days, from December 20, 2022, to January 4, 2023. This compliance with Listing Rule 5550(a)(2) means the previous issue is now resolved. SINTX is known for developing advanced ceramics for medical and technical applications, and its products have been in human use since 2008.
SINTX Technologies has secured a Phase I contract worth $150K from the U.S. Missile Defense Agency to enhance electrochemical machining (ECM) for aerospace components. This project focuses on developing corrosion-resistant, dielectric coatings aimed at extending tool life and reducing machining costs. Collaborating with Voxel Innovations, SINTX plans to scale up this technology for prototype development after successful contract completion. The U.S. micromachining market is growing, projected at $2.5 billion in 2019, with the non-traditional machining segment, including ECM, leading market advances.
SINTX Technologies announces a 1-for-100 reverse stock split for its common stock effective on December 20, 2022. This action aims to meet Nasdaq's minimum bid price requirements. Following the split, every 100 shares will convert to one new share, with adjustments to the exercise prices and shares underlying existing securities. This change will not impact stockholders’ percentage interests, except for fractional shares, which will be rounded up. The company retains its current trading symbol, SINT.
FAQ
What is the current stock price of Sintx Technologies (SINT)?
What is the market cap of Sintx Technologies (SINT)?
